Compare Davita Inc (DVA) vs Schwab US Large Cap Growth ETF (SCHG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Schwab US Large Cap Growth ETF — how do they compare? Davita Inc trades at $178.34 (market cap $11.72B), while Schwab US Large Cap Growth ETF trades at $35.7. The key difference: Schwab US Large Cap Growth ETF is trading nearer its 52-week high, Davita Inc nearer its low. Which is the better fit depends on your goals.
| DVA | SCHG | |
|---|---|---|
Market Cap | $11.72B | — |
Sector | Health | Sector/Thematic |
52-Week High | $240.96 | $35.83 |
52-Week Low | $103.87 | $28.10 |
Enterprise Value | $24.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $183.77, up 1.72% today, with a mixed technical picture showing bearish moving averages but bullish oscillators. The company reported strong Q2 2026 earnings of $4.02 per share, beating estimates, driven by volume growth. Revenue reached $13.64 billion in 2025, with a net income margin of 6.05%. Analyst consensus is a Buy with a $232.25 price target, though technical signals are bearish overall.
The outlook for DVA is cautiously optimistic, supported by earnings beats and volume growth, but risks include reimbursement pressure and high debt levels. The stock offers potential upside to the consensus target, yet investors face headwinds from margin compression and technical bearishness.
SCHG trades at $35.78, up 1.02% today, with a bullish technical signal from moving averages and strong trend strength (ADX). The ETF's low 0.04% expense ratio and concentrated exposure to AI-driven tech giants like Nvidia and Microsoft support growth potential, though key valuation metrics are unavailable. Recent news highlights institutional position adjustments and AI capital expenditure tailwinds.
Outlook remains positive due to AI growth catalysts and cost efficiency, but risks include high concentration in top holdings and sensitivity to tech sector volatility. Analyst sentiment is mixed, with some citing premium valuations as a concern for near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Schwab US Large Cap Growth ETF
SCHG is an ETF that seeks to track the total return of the Dow Jones U.S. Large-Cap Growth Total Stock Market Index. The fund provides low-cost exposure to a diversified portfolio of large-capitalization U.S. companies that are classified as growth stocks based on factors such as sales, earnings, and book value growth rates. SCHG is often used by investors seeking long-term capital appreciation from market-leading companies with above-average growth potential.
Read more on SCHG →
